Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7320526 | PMC |
| http://dx.doi.org/10.1016/j.jegh.2014.12.004 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Development of benznidazole orally disintegrating tablets for paediatric patients.
J Pharm Pharmacol
September 2025
Facultad de Farmacia y Bioquímica, Departamento de Tecnología Farmacéutica, Cátedra de Tecnología Farmacéutica II, Universidad de Buenos Aires, C1113AAD Buenos Aires, Argentina.
Objectives: To develop the orphan drug benznidazole (BNZ) in orally disintegrating tablets, for the neglected disease American Trypanosomiasis (Chagas disease) therapy. Although children are highly affected by this disease, there are no specific commercial pharmaceutical preparations for this age group in Argentina and in many other countries.
Methods: In the production process, co-milling in a ball mill was applied to enhance dissolution rates, followed by direct compression.
Program Evaluation of an Adolescent Intervention Program: Substance Use Education Program for At-Risk Adolescents.
J Addict Nurs
August 2025
Brandy Mechling, PhD, RN, PMHCNS-BC, FNAP, University of North Carolina Wilmington, Wilmington, NC.
In the United States, approximately 20 million individuals, age 12 and older, have a substance use disorder (SUD), with an average age of first-time use at 13 years old. Evidence has shown that many SUDs begin in adolescence, and involvement with the legal system can ensue. Adolescents with first-time drug and alcohol arrests can be referred to an Adolescent Intervention Program (AIP) as an alternative to jailtime from the juvenile court system.
View Article and Find Full Text PDFPharmacokinetic Study and Bioequivalence Evaluation of Two Sustained-Release Tablets of Tamsulosin in Healthy Chinese Subjects Under Fasting and Postprandial Conditions.
Clin Pharmacol Drug Dev
September 2025
Phase I Clinical Research Centre, Wuhan Pulmonary Hospital, Wuhan, China.
Tamsulosin is a highly selective α1A adrenergic receptor antagonist that can relax smooth muscles in the urethra, bladder neck, and prostate and improve urinary disorders. It is therefore widely used to treat lower urinary tract symptoms caused by benign prostatic hyperplasia. The aim of this study is to evaluate the pharmacokinetic (PK) characteristics and bioequivalence of 2 different formulations (tamsulosin sustained-release tablets and tamsulosin sustained-release capsules) in healthy Chinese subjects.
View Article and Find Full Text PDFA Pilot Study on the Estimation of Bite Force Using Electromyograms of the Masticatory Muscles.
J Oral Rehabil
September 2025
Center for Advanced Oral Medicine, Hokkaido University Hospital, Sapporo, Japan.
Background: It has not been established how electromyographic (EMG) data of masticatory muscles can estimate bite force (BF) during daily activities at home, such as eating and bruxism, utilising the EMG-BF correlation.
Objective: This study aimed to investigate the relationship between actual BF and BF estimated using corresponding EMG data and additional information on BF and EMG measured on a separate day.
Methods: Participants were 16 volunteers.
Developing and validating a bi-polar gated respiratory motion management strategy for improved lung stereotactic body radiotherapy treatment.
Cancer Pathog Ther
September 2025
Department of Radiation Oncology, Duke University Medical Center, Durham, NC 27708, United States.
Background: Stereotactic body radiotherapy (SBRT) is an effective treatment for early-stage non-small cell lung cancer. However, patient breathing can affect treatment accuracy. Therefore, this study aimed to develop a bi-polar (BP) gated motion management strategy for SBRT and evaluate its feasibility geometrically and dosimetrically.
View Article and Find Full Text PDF